Cyclo Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Cyclo Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Narrow-pipeline pure-play on cyclodextrin platform targeting rare neurological diseases; success contingent on Phase 3 NPC1 results and Alzheimer's expansion potential. Cyclo is advancing Phase 3 and Phase 2b trials with orphan drug designations in rare but serious indications. However, as a micro-cap clinical-stage company with limited revenue and ongoing.
What is Cyclo Therapeutics, Inc.'s industry? Cyclo Therapeutics, Inc. (cyclotherapeutics.com) operates in Biotechnology - Clinical-Stage Therapeutics (Rare Disease and Neurodegenerative Focus). AskCyborg classifies Cyclo Therapeutics, Inc. under Biotechnology - Clinical-Stage Therapeutics (Rare Disease and Neurodegenerative Focus) in its company registry.
Cyclo Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases. The lead therapeu...
Cyborg Score thesis
Narrow-pipeline pure-play on cyclodextrin platform targeting rare neurological diseases; success contingent on Phase 3 NPC1...
Read the full analyst-debate transcript →Get the Latest Cyclo Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCyclo Therapeutics, Inc. Overview
Pro stress-test →Cyclo Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases. The lead therapeutic asset is Trappsol® Cyclo™, a proprietary formulation of hydroxypropyl beta cyclodextrin that has shown encouraging results to effectively manage the transportation of cholesterol.
Strategic Profile
Pro stress-test →The company's primary focus is advancing its pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer's disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Competitive Landscape
Pro stress-test →Cyclo operates in the rare disease and neurodegenerative disease treatment space with minimal direct competition in orphan drug-designated indications. Broader Alzheimer's disease market includes large pharma players (Eisai, Eli Lilly, Roche) pursuing amyloid-targeting and other mechanisms, but Cyclo's cyclodextrin cholesterol management approach is differentiated. As a clinical-stage company with limited resources, Cyclo's competitive advantage derives from orphan drug status and early clinical evidence rather than scale.
Industry Context
Cyclo Therapeutics, Inc. operates in Biotechnology - Clinical-Stage Therapeutics (Rare Disease and Neurodegenerative Focus).
Key facts
Founded: 1990 · Headquarters: Gainesville, Florida · Employees: N/A · Revenue: N/A · Market cap: N/A